CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,095 enrolled
Drug / intervention
telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00904215
NCT00904215N/ACompleted
CompareCT.gov

A Post Marketing Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Boehringer Ingelheim·observational·Posted May 19, 2009·Updated Apr 21, 2014

In Brief

An observational study evaluating telmisartan/telmisartan + HCTZ (Hydrochlorothiazide) for Hypertension. Completed, enrolled 1,095 participants across 11 sites.

Detailed Summary

An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hypertension

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 19, 2009
Enrollment StartFeb 1, 2005
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.1 years ago

Interventions

telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)drug